<?xml version='1.0' encoding='utf-8'?>
<document id="31173645"><sentence text="Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite."><entity charOffset="55-66" id="DDI-PubMed.31173645.s1.e0" text="quizartinib" /></sentence><sentence text="Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia"><entity charOffset="0-11" id="DDI-PubMed.31173645.s2.e0" text="Quizartinib" /><entity charOffset="77-85" id="DDI-PubMed.31173645.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.31173645.s2.e0" e2="DDI-PubMed.31173645.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31173645.s2.e0" e2="DDI-PubMed.31173645.s2.e1" /></sentence><sentence text=" This drug-drug interaction study assessed the pharmacokinetics (PK) of quizartinib when coadministered with strong or moderate cytochrome P450 3A (CYP3A) inhibitors"><entity charOffset="72-83" id="DDI-PubMed.31173645.s3.e0" text="quizartinib" /></sentence><sentence text="" /><sentence text="In this parallel-group study, subjects were randomised to receive: (i) quizartinib + ketoconazole; (ii) quizartinib + fluconazole; or (iii) quizartinib alone"><entity charOffset="71-97" id="DDI-PubMed.31173645.s5.e0" text="quizartinib + ketoconazole" /><entity charOffset="104-129" id="DDI-PubMed.31173645.s5.e1" text="quizartinib + fluconazole" /><entity charOffset="140-151" id="DDI-PubMed.31173645.s5.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31173645.s5.e0" e2="DDI-PubMed.31173645.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31173645.s5.e0" e2="DDI-PubMed.31173645.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s5.e0" e2="DDI-PubMed.31173645.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31173645.s5.e1" e2="DDI-PubMed.31173645.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s5.e1" e2="DDI-PubMed.31173645.s5.e2" /></sentence><sentence text=" On Days 1-28, subjects received ketoconazole 200 mg or fluconazole 200 mg twice daily, and on Day 8, all subjects received a single 30-mg quizartinib dose"><entity charOffset="33-45" id="DDI-PubMed.31173645.s6.e0" text="ketoconazole" /><entity charOffset="56-67" id="DDI-PubMed.31173645.s6.e1" text="fluconazole" /><entity charOffset="139-150" id="DDI-PubMed.31173645.s6.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31173645.s6.e0" e2="DDI-PubMed.31173645.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31173645.s6.e0" e2="DDI-PubMed.31173645.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s6.e0" e2="DDI-PubMed.31173645.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31173645.s6.e1" e2="DDI-PubMed.31173645.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s6.e1" e2="DDI-PubMed.31173645.s6.e2" /></sentence><sentence text=" Blood samples were collected for PK analyses, steady-state PK parameters were simulated by superpositioning, and safety was assessed" /><sentence text="" /><sentence text="Ninety-three healthy subjects were randomised; 86 completed the study" /><sentence text=" When administered with ketoconazole, geometric mean ratios (90% confidence interval) for quizartinib maximum observed plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) from time 0 extrapolated to infinity were 117% (105%, 130%) and 194% (169%, 223%), respectively, vs quizartinib alone"><entity charOffset="24-36" id="DDI-PubMed.31173645.s10.e0" text="ketoconazole" /><entity charOffset="90-101" id="DDI-PubMed.31173645.s10.e1" text="quizartinib" /><entity charOffset="305-316" id="DDI-PubMed.31173645.s10.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31173645.s10.e0" e2="DDI-PubMed.31173645.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31173645.s10.e0" e2="DDI-PubMed.31173645.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s10.e0" e2="DDI-PubMed.31173645.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31173645.s10.e1" e2="DDI-PubMed.31173645.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s10.e1" e2="DDI-PubMed.31173645.s10.e2" /></sentence><sentence text=" Steady-state PK simulation demonstrated ~2-fold increase of both steady-state Cmax and AUC from time 0 to the end of the dosing interval when quizartinib was administered with ketoconazole due to accumulation of quizartinib at steady state"><entity charOffset="143-154" id="DDI-PubMed.31173645.s11.e0" text="quizartinib" /><entity charOffset="177-189" id="DDI-PubMed.31173645.s11.e1" text="ketoconazole" /><entity charOffset="213-224" id="DDI-PubMed.31173645.s11.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31173645.s11.e0" e2="DDI-PubMed.31173645.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31173645.s11.e0" e2="DDI-PubMed.31173645.s11.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s11.e0" e2="DDI-PubMed.31173645.s11.e2" /><pair ddi="false" e1="DDI-PubMed.31173645.s11.e1" e2="DDI-PubMed.31173645.s11.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s11.e1" e2="DDI-PubMed.31173645.s11.e2" /></sentence><sentence text=" When administered with fluconazole, geometric mean ratios (90% confidence interval) for quizartinib Cmax and AUC from time 0 extrapolated to infinity were 111% (100%, 124%) and 120% (104%, 138%), respectively, vs quizartinib alone"><entity charOffset="24-35" id="DDI-PubMed.31173645.s12.e0" text="fluconazole" /><entity charOffset="89-100" id="DDI-PubMed.31173645.s12.e1" text="quizartinib" /><entity charOffset="214-225" id="DDI-PubMed.31173645.s12.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31173645.s12.e0" e2="DDI-PubMed.31173645.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31173645.s12.e0" e2="DDI-PubMed.31173645.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s12.e0" e2="DDI-PubMed.31173645.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31173645.s12.e1" e2="DDI-PubMed.31173645.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31173645.s12.e1" e2="DDI-PubMed.31173645.s12.e2" /></sentence><sentence text=" Overall, 5" /><sentence text="4% of subjects experienced quizartinib-related adverse events; no serious adverse events or deaths occurred"><entity charOffset="27-38" id="DDI-PubMed.31173645.s14.e0" text="quizartinib" /></sentence><sentence text="" /><sentence text="These results suggest reducing the dose of quizartinib when coadministered with a strong CYP3A inhibitor, but not with a moderate or weak CYP3A inhibitor"><entity charOffset="43-54" id="DDI-PubMed.31173645.s16.e0" text="quizartinib" /></sentence><sentence text=" This dose reduction was implemented in phase 3 evaluation of quizartinib"><entity charOffset="62-73" id="DDI-PubMed.31173645.s17.e0" text="quizartinib" /></sentence><sentence text="" /></document>